Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx to Develop Biochips Using Dyax s Phage Display Technology

NEW YORK, March 27 - In an effort to develop its protein biochips, Zyomyx said Tuesday it has licensed phage display antibody technology from Dyax.

The agreement is the second antibody collaboration for Zyomyx, which first teamed up with Cambridge Antibody Technology (CAT) last December for access to antibodies in CAT's phage display libraries. 

In the arrangement with Dyax, Zyomyx will receive a non-exclusive license to Dyax's phage display technology for developing antibodies to specific proteins for use in a protein biochip. The companies did not disclose financial terms of the deal, but said that the agreement involves both fees for R&D and royalties on future product sales.

Last week, diagnostics manufacturer Biosite said it had developed a prototype protein microarray with 100 antibodies. While Zyomyx has yet to announce the development of a large-scale prototype, Zyomyx CEO Lawrence Cohen said recently that the company plans to release beta versions of chips that will have densities of up to 10,000 proteins per square centimeter later this year.

Zyomyx, of Hayward, Calif., also has partnerships with Fujirebo, a Japanese developer of diagnostics tools, and MDS Proteomics of Toronto.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.